Table 1 Clinical and Molecular Characteristics of SickKids cohort with PLGG
From: Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma
|  | All (N = 363) | KIAA1549-BRAF fusion (N = 130) | No Fusion (N = 233) |
|---|---|---|---|
Age in years at diagnosis, mean (range) | 9.8 (0.2–18.5) | 9.0 (0.3–17.7) | 10.2 (0.2–18.5) |
Fused, % | 35.81 | 100.00 | 0.00 |
Female, % | 49.58 | 54.62 | 46.67 |
Follow up in years, mean (range) | Â | Â | Â |
mortality outcome | 8.9 (0.0–30.1) | 7.7 (0.0–29.4) | 9.6 (0.1–30.1) |
progression outcome | 5.3 (0.0–22.8) | 4.7 (0.0–21.6) | 5.6 (0.0–22.8) |
Died, N (%) | 19 (5.23) | 3 (2.31) | 16 (6.87) |
Progressed, N (%) | 113 (31.13) | 35 (26.92) | 78 (33.48) |